A Novel Prognostic and Predictive Signature for Lung Adenocarcinoma Derived from Combined Hypoxia and Infiltrating Immune Cell-Related Genes in TCGA Patients

References

• Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):138–155. doi:10.3322/caac.21390
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259–1271. doi:10.1016/j.cell.2017.10.001
   PubMed Web of Science ®Google Scholar
• Zhou B, Flodby P, Luo J, et al. Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis. J Clin Invest. 2018;128(3):970–984. doi:10.1172/JCI90429
   PubMed Web of Science ®Google Scholar
• Zhang Z, Tang H, Chen P, Xie H, Tao Y. Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome. Signal Transduct Target Ther. 2019;4:41. doi:10.1038/s41392-019-0074-5
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Goding SA, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–164. doi:10.3322/caac.21601
   PubMed Web of Science ®Google Scholar
• Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg. 2018;153(6):588–589. doi:10.1001/jamasurg.2018.0501
   PubMed Web of Science ®Google Scholar
• Chen J, Liao Y, Fan X. Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis. Expert Rev Anticancer Ther. 2021;21(7):795–803. doi:10.1080/14737140.2021.1908132
   PubMed Web of Science ®Google Scholar
• Liao Y, He D, Wen F. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy. Immunogenetics. 2021;73(5):369–380. doi:10.1007/s00251-021-01223-8
   PubMed Web of Science ®Google Scholar
• Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS. Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer. 2017;3(7):529–541. doi:10.1016/j.trecan.2017.05.002
   PubMed Web of Science ®Google Scholar
• Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol. 2012;9(12):674–687. doi:10.1038/nrclinonc.2012.171
   PubMed Web of Science ®Google Scholar
• Macklin PS, McAuliffe J, Pugh CW, Yamamoto A. Hypoxia and HIF pathway in cancer and the placenta. Placenta. 2017;56:8–13. doi:10.1016/j.placenta.2017.03.010
   PubMed Web of Science ®Google Scholar
• Mo Z, Yu L, Cao Z, Hu H, Luo S, Zhang S. Identification of a hypoxia-associated signature for lung adenocarcinoma. Front Genet. 2020;11:647. doi:10.3389/fgene.2020.00647
   PubMed Web of Science ®Google Scholar
• Damgaci S, Ibrahim-Hashim A, Enriquez-Navas PM, Pilon-Thomas S, Guvenis A, Gillies RJ. Hypoxia and acidosis: immune suppressors and therapeutic targets. Immunology. 2018;154(3):354–362. doi:10.1111/imm.12917
   PubMed Web of Science ®Google Scholar
• Chen W, Dai X, Chen Y, et al. Significance of STAT3 in immune infiltration and drug response in cancer. Biomolecules. 2020;10(6):834. doi:10.3390/biom10060834
   PubMed Web of Science ®Google Scholar
• Caputo S, Grioni M, Brambillasca CS, et al. Galectin-3 in prostate cancer stem-like cells is immunosuppressive and drives early metastasis. Front Immunol. 2020;11:1820. doi:10.3389/fimmu.2020.01820
   PubMed Web of Science ®Google Scholar
• Sun J, Zhao T, Zhao D, et al. Development and validation of a hypoxia-related gene signature to predict overall survival in early-stage lung adenocarcinoma patients. Ther Adv Med Oncol. 2020;12:431414352. doi:10.1177/1758835920937904
   Web of Science ®Google Scholar
• Shi R, Bao X, Unger K, et al. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients. Theranostics. 2021;11(10):5061–5076. doi:10.7150/thno.56202
   PubMed Web of Science ®Google Scholar
• Sun S, Guo W, Wang Z, et al. Development and validation of an immune-related prognostic signature in lung adenocarcinoma. Cancer Med. 2020;9(16):5960–5975. doi:10.1002/cam4.3240
   PubMed Web of Science ®Google Scholar
• Yang S, Liu T, Cheng Y, Bai Y, Liang G. Immune cell infiltration as a biomarker for the diagnosis and prognosis of digestive system cancer. Cancer Sci. 2019;110(12):3639–3649. doi:10.1111/cas.14216
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi:10.1038/nrc.2016.36
   PubMed Web of Science ®Google Scholar
• Darvin P, Toor SM, Sasidharan NV, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–11. doi:10.1038/s12276-018-0191-1
   PubMed Web of Science ®Google Scholar
• Luo W, Wang Y. Hypoxia mediates tumor malignancy and therapy resistance. Adv Exp Med Biol. 2019;1136:1–18.
   PubMed Web of Science ®Google Scholar
• Vito A, El-Sayes N, Mossman K. Hypoxia-driven immune escape in the tumor microenvironment. Cells-Basel. 2020;9(4):992.
   PubMed Web of Science ®Google Scholar
• Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018;13:6049–6058. doi:10.2147/IJN.S140462
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang J, Xing H, Li Q, Zhao Q, Li J. Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells. Mol Cell Biochem. 2016;411(1–2):331–340. doi:10.1007/s11010-015-2595-8
   PubMed Web of Science ®Google Scholar
• Cong J, Wang X, Zheng X, et al. Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression. Cell Metab. 2018;28(2):243–255. doi:10.1016/j.cmet.2018.06.021
   PubMed Web of Science ®Google Scholar
• Dong Y, Huaying S, Danying W, et al. Significance of methylation of FBP1 gene in non-small cell lung cancer. Biomed Res Int. 2018;2018:3726091. doi:10.1155/2018/3726091
   PubMed Web of Science ®Google Scholar
• Huang X, Li X, Xie X, et al. High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. Breast. 2016;30:39–46. doi:10.1016/j.breast.2016.08.014
   PubMed Web of Science ®Google Scholar
• Gao S, Tu DN, Li H, et al. Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma. Biomed Pharmacother. 2016;81:388–393. doi:10.1016/j.biopha.2016.04.029
   PubMed Web of Science ®Google Scholar
• Yu C, Hou L, Cui H, et al. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma. Future Oncol. 2018;14(24):2483–2492. doi:10.2217/fon-2018-0177
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang J, Yuan C, et al. Establishment of the Prognostic index reflecting tumor immune microenvironment of lung adenocarcinoma based on metabolism-related genes. J Cancer. 2020;11(24):7101–7115. doi:10.7150/jca.49266
   PubMed Web of Science ®Google Scholar
• Yu X, Zhang X, Zhang Y. Identification of a 5-gene metabolic signature for predicting prognosis based on an integrated analysis of tumor microenvironment in lung adenocarcinoma. J Oncol. 2020;2020:5310793. doi:10.1155/2020/5310793
   PubMed Web of Science ®Google Scholar
• Wang Z, Embaye KS, Yang Q, et al. Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes. Cancer Cell Int. 2021;21(1):219. doi:10.1186/s12935-021-01915-x
   PubMed Web of Science ®Google Scholar
• Guo Z, Zhu H, Xu W, et al. Alternative splicing related genetic variants contribute to bladder cancer risk. Mol Carcinog. 2020;59(8):923–929. doi:10.1002/mc.23207
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Xing P, et al. Development and validation of a hypoxia-related prognostic signature for breast cancer. Oncol Lett. 2020;20(2):1906–1914. doi:10.3892/ol.2020.11733
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cedervall J, Hamidi A, et al. Platelet-specific PDGFB ablation impairs tumor vessel integrity and promotes metastasis. Cancer Res. 2020;80(16):3345–3358. doi:10.1158/0008-5472.CAN-19-3533
   PubMed Web of Science ®Google Scholar
• Zhang D, Cui G, Sun C, et al. Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-beta axis. Biochem Biophys Res Commun. 2019;512(2):360–366. doi:10.1016/j.bbrc.2019.03.040
   PubMed Web of Science ®Google Scholar
• Li S, Yao H, Xu J, Jiang S. Synthetic routes and biological evaluation of largazole and its analogues as potent histone deacetylase inhibitors. Molecules. 2011;16(6):4681–4694. doi:10.3390/molecules16064681
   PubMed Web of Science ®Google Scholar
• Li R, Liu X, Zhou XJ, et al. Identification and validation of the prognostic value of immune-related genes in non-small cell lung cancer. Am J Transl Res. 2020;12(9):5844–5865.
   PubMed Web of Science ®Google Scholar
• Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001;108(4):497–501. doi:10.1172/JCI200113712
   PubMed Web of Science ®Google Scholar
• Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle. 2008;7(18):2787–2790. doi:10.4161/cc.7.18.6672
   PubMed Web of Science ®Google Scholar
• Thu KL, Soria-Bretones I, Mak TW, Cescon DW. Targeting the cell cycle in breast cancer: towards the next phase. Cell Cycle. 2018;17(15):1871–1885. doi:10.1080/15384101.2018.1502567
   PubMed Web of Science ®Google Scholar
• Maheswari U, Sadras SR. Mechanism and regulation of autophagy in cancer. Crit Rev Oncog. 2018;23(5–6):269–280. doi:10.1615/CritRevOncog.2018028394
   PubMedGoogle Scholar
• Chen J, Wu F, Shi Y, et al. Identification of key candidate genes involved in melanoma metastasis. Mol Med Rep. 2019;20(2):903–914. doi:10.3892/mmr.2019.10314
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304–317. doi:10.1016/j.ccr.2014.01.021
   PubMed Web of Science ®Google Scholar
• Lim S, Liu H, Madeira DSL, et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1alpha. Cancer Res. 2016;76(8):2231–2242. doi:10.1158/0008-5472.CAN-15-1538
   PubMed Web of Science ®Google Scholar
• Huang L. The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion. Eur Rev Med Pharmacol Sci. 2020;24(12):6759–6766. doi:10.26355/eurrev_202006_21664
   PubMed Web of Science ®Google Scholar
• Li Y, Yang X, Wu Y, et al. B7-H3 promotes gastric cancer cell migration and invasion. Oncotarget. 2017;8(42):71725–71735. doi:10.18632/oncotarget.17847
   PubMedGoogle Scholar
• Flem-Karlsen K, Fodstad O, Tan M, Nunes-Xavier CE. B7-H3 in cancer - beyond immune regulation. Trends Cancer. 2018;4(6):401–404. doi:10.1016/j.trecan.2018.03.010
   PubMed Web of Science ®Google Scholar
• Zhang C, Hao X. Prognostic significance of CD276 in non-small cell lung cancer. Open Med (Wars). 2019;14:805–812. doi:10.1515/med-2019-0076
   PubMedGoogle Scholar
• Wang C, Li Y, Jia L, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021;28:1597–1613.e7. doi:10.1016/j.stem.2021.04.011
   PubMed Web of Science ®Google Scholar